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Omapatrilat inhibits both angiotensin-converting en-
zyme (ACE) and neutral endopeptidase (NEP). ACE in-
hibitors have been shown to inhibit atherosclerosis in
apoE-deﬁcient mice and in several other animal mod-
els but failed in low-density lipoprotein (LDL) receptor–
deﬁcient mice despite effective inhibition of the renin-
angiotensin-aldosterone system. The aim of the present
studywastoexaminetheeffectofomapatrilatonatheroge-
nesis in diabetic and nondiabetic LDL receptor–deﬁcient
mice. LDL receptor–deﬁcient male mice were randomly
divided into 4 groups (n D 11 each). Diabetes was induced
in 2 groups by low-dose STZ, the other 2 groups served
as nondiabetic controls. Omapatrilat (70 mg/kg/day)
was administered to one of the diabetic and to one of
the nondiabetic groups. The diabetic and the nondia-
betic mice were sacriﬁced after 3 and 5 weeks, respec-
tively. The aortae were examined and the atherosclerotic
plaque area was measured. The atherosclerotic plaque
area was signiﬁcantly smaller in the omapatrilat-treated
mice, both diabetic and nondiabetic, as compared to non-
treated controls. The mean plaque area of omapatrilat-
treated nondiabetic mice was 9357§7293 ¹m2, versus
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71977§34610 ¹m2 in the nontreated mice (P D .002). In
thediabeticanimals,theplaqueareawas8887§5386¹m2
and 23220§10400 ¹m2, respectively for treated and non-
treated mice (P D .001). Plasma lipids were increased by
omapatrilat:Meanplasmacholesterolintreatedmice,dia-
beticandnondiabeticcombined,was39.31§6.00mmol/L,
versus 33.12§7.64 mmol/L in the nontreated animals
(P D .008). The corresponding combined mean values of
triglycerides were 4.83§1.93 versus 3.00§1.26 mmol/L
(P D .02). Omapatrilat treatment did not affect weight
or plasma glucose levels. Treatment with omapatrilat
inhibits atherogenesis in diabetic as well as nondia-
betic LDL receptor–deﬁcient mice despite an increase in
plasma lipids, suggesting a direct effect on the arterial
wall.
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Vasopeptidaseinhibition(VPI)involvessimultaneousinhi-
bition,withasinglemolecule,of2keyenzymes:angiotensin-
converting enzyme (ACE) and neutral endopeptidase (NEP)
[1]. NEP has been reported to hydrolyze a number of endoge-
nous vasoactive peptides, such as bradykinin and substance P,
and is the principal enzyme degrading the natriuretic peptides
[2]. By inhibition of the renin angiotensin aldosterone sys-
tem (RAAS) and simultaneous potentiation of the natriuretic
peptidesystem,VPIsreducevasoconstrictionandenhanceva-
sodialation [1]. Recently, Arnal and colleagues [3] reported
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that omapatrilat, a novel vasopeptidase inhibitor, prevented
fatty streak deposition in apoE-deﬁcient mice.
AngiotensinIIwasrecentlyfoundtoaccelerateatheroscle-
rosis in apoE-deﬁcient mice and in low-density lipoprotein
(LDL) receptor–deﬁcient mice [4, 5]. ACE inhibitors reduce
circulating levels of angiotensin II and were shown to inhibit
LDL oxidation and retard atherosclerosis in apoE-deﬁcient
mice [6]. Atherosclerosis was attenuated by ACE inhibitors
alsoinotherexperimentalmodelsofatherogenesis[7–13].No
effect could be demonstrated, however, in the LDL receptor–
deﬁcient mouse model [14] nor in the Watanabe heritable
hyperlipidemic rabbit model [15].
Thepresentstudyaimedtoﬁndwhetheromapatrilatwould
attenuate atherogenesis in diabetic (streptozotocin [STZ]-
induced) and nondiabetic LDL receptor–deﬁcient mice.
METHODS
Animals
LDL receptor–deﬁcient mice with a C57BL/6 background
were obtained from the Jackson Laboratory (Bar Harbor,
Maine,USA)andbredinalocalanimalhouse(Sheba-Medical
Center, Israel) on regular chow and water ad libitum. At 6
weeks of age, the mice were divided into 4 groups 14 mice
each.Insomeoftheanimals,veryloworveryhighlipidlevels
precluded their use. Finally, 11 animals were included in each
group.Diabeteswasinducedin2groupsusinglow-doseSTZ.
Upon conﬁrmation of diabetes, the mice were fed Western-
styledietconsistingof0.01%addedcholesteroland21%milk
fat (TD98338; Harlan-Tekland, Madison, Wisconsin, USA).
The animals were placed in a 12-hour light cycle and had
ab libitum access to water. The animal experiments were
performed according to National Institutes of Health (NIH)
guidelines. The protocol was approved by the Sheba Medical
Center Animal Subject Committee.
Induction of Diabetes
To induce diabetes, STZ (Sigma), 50 mg/kg/day, in cit-
rated buffer (pH D 7.4), was injected intraperitoneally for
5 consecutive days [16]. Glucose levels were determined in
blood drawn from the retro-orbital plexus using Accutrend
GC (Boeringer). The mice were considered diabetic if they
had blood glucose levels higher than 250 mg/dL (15 mmol/L)
at 2-hour fast. Omapatrilat, dissolved in water at a dose of
70 mg/kg/day was given using oral needle gavage. Control
animals were gavaged with water.
Cholesterol and Triglyceride Determination
Total 12-hour fasting plasma cholesterol and triglyceride
levels were determined using an automated enzymatic tech-
nique (Boehringer-Mannheim, Germany). The blood was
drawnfromtheretro-orbitalplexusbyaﬁnepipettewith10%
EDTA.
Tissue Preparation and Morphometric
Analysis of Atherosclerotic Lesions
The heart was perfused from its apex with cold phosphate-
buffered saline (PBS) via a canula placed in the left ventri-
cle, with ﬂuid drained from the right atrium. The hearts from
the PBS-perfused mice were severed from the aorta at the
base,embededinOCT,andfrozen.Everyothersection(10¹)
throughout the aortic sinus was taken for analysis. Sections
were evaluated for fatty streak lesions after staining with oil
Red-O. Quantitation of atherosclerosis was performed with a
high-resolution camera using computer-assisted image anal-
ysis, by an observer blinded to tissue identity.
Statistical Analysis
The primary end point of the study was the atherosclerotic
plaque area in the aorta. Based on a presumed 25% reduction
of the plaque area by omapatrilate, 10 animals were needed in
each group for a power of 0.8 and a type 1 error of 0.05. The
data of the different groups were compared by 1-way analysis
ofvarianceandthenbyStudent’st testforunpaireddatausing
SigmaStat software. Data are expressed as mean § SD. P <
.05 was accepted as statistically signiﬁcant.
RESULTS
Following the start of omapatrilat, the experiment lasted
5 weeks for the nondiabetic mice and 3 weeks for the diabetic
mice. Four of the mice died. The ﬁrst died immediately fol-
lowing an injection of STZ and the other three, one in each
group, during the experiment. The omapatrilat-treated mice
and the controls had a similar weight gain. At the beginning
ofthestudy,therewerenosigniﬁcantdifferencesinweightbe-
tween the mice of the 4 groups. As expected, the STZ-treated
micegainedsigniﬁcantlylessweightthanthenontreatedmice
(mean 0.05§2.4 g versus 1.75§1.4 g, respectively; P D
.009). Omapatrilat treatment had no effect on weight gain in
either the diabetic or the nondiabetic mice (mean ¡0.2§2.3
g versus 0.3§2.5 g, respectively, for treated and nontreated
diabetic mice; and a mean of 1.4§1.7 g versus 2.1§1.1 g,
respectively, for the nondiabetic mice) (Table 1).
Plasma Glucose Levels
TheSTZ-treatedmicehadsigniﬁcantlyhigherplasmaglu-
coselevelsthannontreatedanimals(mean22.9§4.8mmol/L
versus 6.9§0.9 mmol/L, respectively; P D .001). Plasma
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TABLE 1
Body weight, plasma glucose, triglycerides, and cholesterol
levels in omapatrilate-treated animals versus controls in
diabetic and nondiabetic mice
Start (g) Weight gain (g)
Body weight
Diabetes,a no treatment 24.0§4.4 0.3§2.5
Diabetes,a omapatrilatb 22.3§3.0 ¡0.2§2.3
No diabetes, no treatment 24.0§4.4 2.1§1.1
No diabetes, omapatrilatb 23.4§3.7 1.4§1.7
Start (mmol/L) End (mmol/L)
Plasma glucose
Diabetes,c no treatment 15.4§4.1 22.8§6.2
Diabetes,c omapatrilatd 16.8§3.9 22.9§2.9
No diabetes, no treatment 6.7§1.2 7.0§1.5
No diabetes, omapatrilatd 4.7§1.4 6.8§0.7
Plasma triglyceride
Diabetes,e no treatment 1.6§0.5 10.8§5.6
Diabetes,e omapatrilat 1.4§0.6 14.5§5.8
No diabetes, no treatment 1.5§0.5 3.0§1.3
No diabetes, omapatrilat f 2.1§0.8 4.8§1.9
Plasma cholesterol
Diabetes,g no treatment 5.1§1.2 33.9§8.2
Diabetes,g omapatrilath 5.4§0.9 39.5§6.6
No diabetes, no treatment 5.0§1.3 33.2§7.4
No diabetes, omapatrilath 5.5§1.3 39.2§5.7
aDiabetes induction resulted in a signiﬁcantly lower weight gain
(P D :009).
bOmapatrilat treatment did not affect weight gain.
cDiabetes induction resulted in a signiﬁcantly higher plasma
glucose leveles (P D :001).
dOmapatrilat treatment did not affect plasma glucose levels.
eDiabetes induction resulted in a signiﬁcant increase in plama
triglyceride levels (P D :001).
fOmapatrilat treatment resulted in a signiﬁcant increase in plama
triglyceride levels only among the nondiabetic mice (P D :02).
gDiabetes induction did not affect plasma cholesterol levels.
hOmapatrilattreatmentresultedinasigniﬁcantincreaseinplasma
cholesterol levels (P D :008).
diabetic or the nondiabetic groups (mean 22.9§2.9 mmol/L
versus 22.8§ 6.2 mmol/L, respectively, for the diabetic
mice, P D .49; and a mean of 6.8§0.7 mmol/L versus
7.0§1.5mmol/L,respectively,forthenondiabeticmice, P D
.77) (Table 1).
Plasma Lipids
The STZ diabetic mice had signiﬁcantly higher plasma
levels of triglycerides than the control mice (mean
11.9§5.9 mmol/L versus 3.5§1.8 mmol/L, respectively;
P D .001). Omapatrilat treatment was associated with an in-
crease in plasma levels of triglycerides in the diabetic as well
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FIGURE 1
Plasma triglyceride levles. LDL receptor–deﬁcient mice
were divided into 4 groups (n D 11). Diabetes was induced
in 2 groups using low-dose STZ, and 2 groups remained
euglycemic. Omapatrilat was administered to one of the
diabetic and one of the nondiabetic groups. Diabetes
induced a signiﬁcant rise in plasma triglycerides.
Omapatrilat treatment resulted in a rise in plasma
triglyceride level in both diabetic and nondiabetic mice.
as in the nondiabetic animals. The increase was statistically
signiﬁcant only in the non-diabetic group (mean 14.5§5.8
mmol/L versus 10.8§5.6 mmol/L, respectively, for the di-
abetic mice, P D .16; and a mean of 4.8§1.9 mmol/L
versus 3.0§1.3 mmol/L, respectively, for the nondiabetic
mice, P D .022) (Table 1, Figure 1). The induction of di-
abetes did not affect the plasma levels of cholesterol (mean
35.9§8.0 mmol/L versus 36.1§7.1 mmol/L, respectively,
in the diabetic and nondiabetic mice). Following treatment
with omapatrilat, there was a signiﬁcant increase in plasma
levels of cholesterol (a mean of 39.5§6.6 mmol/L for the
mice treated with omapatrilat versus 33.2§7.4 mmol/L for
the nontreated mice, P D .008). The rise in cholesterol was
observed in both the diabetic and the nondiabetic animals
(mean 39.5§6.6 mmol/L versus 33.0§8.2 mmol/L, respec-
tively,forthediabeticmice, P D.07;andameanof39.2§5.7
mmol/L versus 33.2§7.4 mmol/L, respectively, for the non-
diabetic mice, P D .06) (Figure 2).
Atherosclerotic Plaque Area
Omapatrilat treatment was associated with a signiﬁcant
reduction of atherosclerotic plaque area in both the diabetic
and the nondiabetic mice. In the diabetic mice treated with
omapatrilat for 3 weeks, the mean aortic sinus plaques area
was 8887§5386 ¹m2, as compared to a signiﬁcantly greater62 Z. LEVY ET AL.
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FIGURE 2
Plasma cholesterol levels. Diabetes induction did no change
plasma cholesterol levels. Omapatrilat treatment resulted in
a rise in plasma cholesterol level in both diabetic and
nondiabetic mice.
area of 23220§10400 ¹m2 in the nontreated animals (P D
.002). A similar pattern was observed also in the nondiabetic
mice, which were treated for 5 weeks, 2 weeks longer than
the diabetic groups. The mean plaque area in the omapatrilat-
treatedmicewas9357§7293¹m2,whereasinthenontreated
mice,itmeasured71977§34610¹m2 (P D.001)(Figure3).
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FIGURE 3
Aortic sinus plaque area. The experiment lasted 3 weeks for
the diabetic mice and 5 weeks for the nondiabetic mice.
Omapatrilat treatment induced a signiﬁcant reduction of
atherosclerosis in both diabetic and nondiabetic mice.
DISCUSSION
The main ﬁnding of this study is that omapatrilat, a dual
ACEandNEPinhibitor,retardsatherogenesisinbothdiabetic
and nondiabetic LDL receptor–deﬁcient mice.
LDL receptor–deﬁcient mice develop atherosclerotic le-
sions throughout the arterial tree and have been repeatedly
used as a model of human atherosclerosis [17].
In this animal model, omapatrilat treatment induced no
change in body weight or in plasma glucose levels in the dia-
betic as well as in the nondiabetic mice. Treatment with oma-
patrilat resulted, however, in an overall signiﬁcant increase in
plasma levels of cholesterol and triglycerides. The increase
was statistically signiﬁcant only in the nondiabetic mice, pos-
sibly due to the masking effect of diabetes on plasma triglyc-
eride levels. A similar pattern was reported by Arnal and col-
leagues [3] in apoE-deﬁcient mice treated with omapatrilat.
The decrease in atherosclerosis induced by omapatrilat in
thediabeticaswellasinthenondiabeticexperimentalanimals
despite a rise in plasma lipid levels is probably an expression
of a direct effect on the arterial wall. The more pronounced
atherosclerosis in the nondiabetic animals is born out by the
longer period of exposure to the atherogenic diet. ACE in-
hibitors were repeatedly reported to counteract atherogenic
stimuli in various experimental models of apoE-deﬁcient
mice, hamsters, rabbits, minipigs, and monkeys [8–13]. A
speciﬁc NEP inhibitor, candoxatril was shown to attenuate
atherosclerosis induced by high-cholesterol diet in rabbits
[18], but failed to reproduce this effect in apoE-deﬁcient mice
[19].
TheantiatherogenicactivityofACEinhibitorsmaybepar-
tially born out by reducing the availability of angiotensin II.
This peptide has been repeatedly found to induce atheroscle-
rosis in experimental models of apoE-deﬁcient and LDL
receptor–deﬁcient mice [4, 5]. Angiotensin II may accelerate
atherosclerosis by several mechanisms. Angiotensin II pro-
motes the expression of vascular cellular adhesion molecule
(VCAM)-1 [20] and of monocyte chemoattractant protein
(MCP)-1[21],stimulatestheproductionoflipid-oxidizingre-
activeoxygenspecies[22],andinducesapoptosisofendothe-
lialcells[23].Chobanianandcolleagues[15]reportedthatthe
antiatherogenic effect of ACE inhibitors in the Watanabe her-
itable hyperlipidemic rabbit model was associated with the
ability to lower blood pressure. A blood pressure lowering
dose of the drug also inhibited atherogenesis. However, when
the dose of the ACE inhibitor was sufﬁcient to reduce serum
and aortic ACE activity, but insufﬁcient to lower blood pres-
sure, atherosclerosis was not reduced. A similar pattern was
observed with irbesartan, an angiotensin II receptor antago-
nist. At a low dose, irbesartan blocked the pressor effect of
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atherosclerosis was not blocked. At higher doses, irbesartan
lowered blood pressure and attenuated atherosclerosis [24].
Blood pressure was not measured in the present experiment.
Thedurationoftheexperiment,3to5weeks,is,inanycase,in-
sufﬁcient to explain reduction of atherosclerosis as secondary
to vasodilatiation. Additional experiments are needed to clar-
ify this issue. It was recently reported that ACE inhibitors
failed to decrease atherosclerosis in LDL receptor–deﬁcient
mice, despite a signiﬁcant inhibition of the renin-angiotensin
aldosterone axis [14]. The dual effect of omapatrilat may in-
duce endothelial changes more effectively than ACE inhibi-
tionalone,thusretardingatherogenesiswhereACEinhibitors
alone fail.
WhetherthedualactionofomapatrilatasanACEinhibitor
and a NEP inhibitor may be translated into a better clinical
outcomeisnotclear.TheresultsoftheIMPRESSstudy,which
compared omapatrilat with the ACE inhibitor lisinopril in pa-
tients with heart failure, suggest a trend in favor of omapatri-
lat on the combined end point of worsening heart failure and
death [25]. The effect of omapatrilat as compared with ACE
inhibition alone deserves further investigation both in animal
and in human studies.
REFERENCES
[1] John, C. B. (1999) Vasopeptidase inhibition: A new concept in
blood pressure management. J. Hypertens., 17(Suppl. 1), S37–
S43.
[2] Roques, B., Noble, F., Dague, V., Fournie-Zaliski, M., and
Beaumont, A. (1993) Neutral endopeptidase 24.11: Structure,
inhibition, and experimental and clinical pharmacology. Phar-
macol. Rev., 45, 87–146.
[3] Arnal, J. F., Castano, C., Maupas, E., Mugniot, A., Darblade,
B.,Gourdy,P.,Michel,J.B.,andBayard,F.(2001)Omapatrilat,
a dual angiotensin-converting enzyme and neutral endopepti-
dase inhibitor, prevents fatty streak deposit in apolipoprotein
E-deﬁcient mice. Atherosclerosis, 155, 291–295.
[4] Alan, D., Micheal, W. M., and Lissa, A. C. (2000) An-
giotensin II promotes atherosclerotic lesions and aneurysms
in apolipoprotein E-deﬁcient mice. J. Clin. Invest., 105, 1605–
1612.
[5] Daughtery, A., and Casis, L. A. (1999) Chronic angiotensin
II infusion promotes atherogenesis in low-density lipoprotein
receptor ¡=¡ mice. Ann. N. Y. Acad. Sci., 892, 108–118
[6] Hayek, T., Attias, J., Breslow, J., and Keidar, S. (1995)
Antiatherosclerotic and antioxidative effects of ACE inhibitors
in apolipoprotein E deﬁcient mice. Circulation, 92, 2998–
3002.
[7] Hernandez-Presa, M., Bustos, C., Ortego, M., Tunon, J.,
Renedo,G.,Ruiz-Ortega,M.,andEdigo,J.(1997)Angiotensin-
converting enzyme inhibition prevents arterial nuclear factor
kappa B activation, monocyte chemoattraction protein-1 ex-
pression, and macrophage inﬁltration in a rabbit model of early
accelerated atherosclerosis. Circulation, 95, 1532–1541.
[8] Hoshida, S., Nishida, M., Yamashita, N., Igarashi, J, Aoki,
K., Hori, M., Kuzuya, T., and Tada, M. (1997) Vascular
angiotensin-converting enzyme activity in cholesterol-fed rab-
bits: Effects of enalapril. Atherosclerosis, 130, 53–59.
[9] Aberg, G., and Ferrer, P. (1990) Effects of captopril on
atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Phar-
macol., 15(Suppl.), S65–S72.
[10] Jacobson, L. S., Persson, K., Aberg, G., Andersson, R. G.,
Karlberg, B. E., and Olsson, A. G. (1994) Antiatherosclerotic
effect of angiotensin-converting enzyme inhibitors captopril
andfosinoprilinhypercholesterolemicminipigs.J.Cardiovasc.
Pharmacol., 24, 670–677.
[11] Kowala, M. C., Valentina, M., Recce, R., Beyer, S., Goller,
N., Durham, S., and Aberg, G. (1998) Enhanced reduction of
atherosclerosis in hamsters treated with pravastatin and capto-
pril: ACE in atheromas provides cellular targets for captopril.
J. Cardiovasc. Pharmacol., 32, 29–38.
[12] Kowala, M. C., Recce, R., Beyer, S., and Aberg, G. (1995)
Regression of early atherosclerosis in hyperlipidemic hamsters
inducedbyfosinoprilandcaptopril.J.Cardiovasc.Pharmacol.,
25, 179–186.
[13] Kowala, M. C., Grove, R. I., and Aberg, G. (1994) Inhibitors
of angiotensin converting enzyme decreases early atheroscle-
rosis in hyperlipidemic hamsters. Fosinopril reduces plasma
cholesterol and captopril inhibits macrophage-foam cell accu-
mulation independently of blood pressure and plasma lipids.
Atherosclerosis, 108, 61–72.
[14] Sharabi,Y.,Grossman,E.,Sherer,Y.,Shaish,A.,Levkovitz,H.,
Bitzur,R.,andHarats,D.(2000)Theeffectofreninangiotensin
axisinhibitiononearlyatherogenesisinLDLreceptor-deﬁcient
mice. Pathobiology, 68, 270–274.
[15] Chobanian, A. V., Hope, S., and Brecher, P. (1995) Dissoci-
ation between the antiatherosclerotic effect of trandopril and
suppressionofserumandaorticangiotensinconvertingenzyme
activity in Watanabe heritable hyperlipidemic rabbits. Hyper-
tension, 25, 1306–1310.
[16] Keren, P., George, J., Shaish, A., Levkovitz, H., Janakovic, Z.,
Afek, A., Goldberg, I., Kopolovic, J., Keren, G., and Harats,
D. (2000) Effect of hyperglycemia and hyperlipidemia on
atherosclerosis in LDL receptor deﬁcient mice. Diabetes, 49,
1064–1069.
[17] Knowles, J. W., and Maeda, N. (2000) Genetic modiﬁers of
atherosclerosis in mice. Atheroscler. Thromb. Vasc. Biol., 20,
2336–2345.
[18] Kugiyama, K., Sugiyama, S., Matsumura, T., Ohta, Y., Doi, H.,
andYasue,H.(1996)Suppressionofatheroscleroticchangesin
cholesterol fed rabbits treated with an oral inhibitor of neutral
endopeptidase21.11(EC3.4.24.11).Atheroscler.Thromb.Vasc.
Biol., 16, 1080–1087.
[19] Grantham, J. A., Schirger, J. A., Wennberg, P. W., Sand-
berg, S., Heublein, D. M., Subkowski, T., and Burnnet,
J. C. (2000) Modulation of functionally active endothelin
converting enzyme by chronic neutral endopeptidase inhibi-
tion in experimental atherosclerosis. Circulation, 101, 1976–
1981.
[20] Tummala, P. E., Chen, X. L., Sundell, C. L., Laursen, J. B.
L., Hammes, P., Alexander, W., Harrison, D. G., and Medford,
R. M. (1999) Angiotensin II induces vascular cell adhesion64 Z. LEVY ET AL.
molecule-1 expression in rat vasculature. Circulation, 100,
1223–1229.
[21] Chen, X. L., Tummala, P. E., Olbrych, M. T., Alexander, R.
W., and Medford, R. M. (1998) Angiotensin II induces mono-
cyte chemoattractant protein-1 gene expression in rat vacular
smooth muscle cells. Circ. Res., 83, 952–959.
[22] Grindling, K. K., Minieri, C. A., Ollerenshaw, J. D., and
Alexander, R. W. (1994) Angiotensin II stimulates NADH and
NADPHoxidaseactivationinculturedvascularsmoothmuscle
cells. Circ. Res., 74, 1141–1148.
[23] Dimmeler, S., Rippmann, V., Weiland, U., Haendeler, J., and
Zeiher, A. M. (1997) Angiotensin II induces apoptosis of
human endothelial cells. Protective effect of nitric oxide. Circ.
Res., 81, 970–976.
[24] Hope, S., Brecher, P., and Chobanian, A. V. (1999) Compar-
ison of the effects of AT1 receptor blockade and angiotensin
convertingenzymeinhibitiononatherosclerosis.Am.J.Hyper-
tens., 12, 28–34.
[25] Rouleau,J.L.,Pfeffer,M.A.,Stewart,D.J.,Issac,D.,Sestier,F.,
Kerut,E.K.,Porter,C.B.,Proulx,G.,Qian,C.,andBlock,A.J.
(2000)Comparisonofvasopeptidaseinhibitor,omapatrilat,and
lisinopril on exercise tolerance and mortality in patients with
heart failure: IMPRESS randomised trial. Lancet, 356, 615–
620.